Intercept Pharmaceuticals Stock Equity Positions Weight
ICPTDelisted Stock | USD 10.31 0.16 1.53% |
Intercept Pharmaceuticals fundamentals help investors to digest information that contributes to Intercept Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Intercept Stock. The fundamental analysis module provides a way to measure Intercept Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intercept Pharmaceuticals stock.
Intercept |
Intercept Pharmaceuticals Company Equity Positions Weight Analysis
Intercept Pharmaceuticals' Percentage of fund asset invested in equity instruments. About 80% of global funds and ETFs carry equity instruments on their balance sheet.
More About Equity Positions Weight | All Equity Analysis
Stock Percentage | = | % of Equities | in the fund |
Funds with most asset allocated to stocks can be subclassified into many different categories such as market capitalization or investment style.
CompetitionAccording to the company disclosure, Intercept Pharmaceuticals has an Equity Positions Weight of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Money Flow Index Now
Money Flow IndexDetermine momentum by analyzing Money Flow Index and other technical indicators |
All Next | Launch Module |
Intercept Fundamentals
Return On Equity | -0.64 | |||
Return On Asset | -0.0723 | |||
Profit Margin | (0.19) % | |||
Operating Margin | 0.02 % | |||
Current Valuation | 695.84 M | |||
Shares Outstanding | 41.81 M | |||
Shares Owned By Insiders | 3.12 % | |||
Shares Owned By Institutions | 81.30 % | |||
Number Of Shares Shorted | 10.19 M | |||
Price To Earning | (3.88) X | |||
Price To Book | 44.19 X | |||
Price To Sales | 1.60 X | |||
Revenue | 285.71 M | |||
Gross Profit | 284.73 M | |||
EBITDA | (61.7 M) | |||
Net Income | (174.86 M) | |||
Cash And Equivalents | 404.78 M | |||
Cash Per Share | 13.58 X | |||
Total Debt | 332.67 M | |||
Debt To Equity | 411.20 % | |||
Current Ratio | 3.22 X | |||
Book Value Per Share | 1.72 X | |||
Cash Flow From Operations | (26.78 M) | |||
Short Ratio | 2.64 X | |||
Earnings Per Share | (4.26) X | |||
Price To Earnings To Growth | (0.69) X | |||
Target Price | 19.0 | |||
Number Of Employees | 341 | |||
Beta | 0.88 | |||
Market Capitalization | 794.36 M | |||
Total Asset | 553.71 M | |||
Retained Earnings | (2.14 B) | |||
Working Capital | 310.05 M | |||
Current Asset | 641.69 M | |||
Current Liabilities | 47.37 M | |||
Z Score | -3.15 | |||
Net Asset | 553.71 M |
About Intercept Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intercept Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intercept Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intercept Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Intercept Stock
If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |